^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Vasforda (bevacizumab biosimilar)
i
Other names: HD204, HD 204
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Hanwha Solutions, Huons, Intas, Prestige BioPharma
Drug class:
VEGF-A inhibitor
Related drugs:
11ms
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients (clinicaltrials.gov)
P3, N=500, Recruiting, Prestige Biopharma Limited | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
Trial completion date • Trial primary completion date • Metastases
|
Avastin (bevacizumab) • carboplatin • paclitaxel • Vasforda (bevacizumab biosimilar)
3years
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
No abstract available
Clinical • New P2 trial
|
ALB (Albumin)
|
Avastin (bevacizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Onivyde (nanoliposomal irinotecan) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
over3years
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer (clinicaltrials.gov)
P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
Clinical • New P2 trial
|
ALB (Albumin)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
almost4years
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
P2; N=96; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2020 --> Jun 2021; Trial primary completion date: Jun 2020 --> Jun 2021
Trial completion date • Trial primary completion date • Clinical
|
MSLN (Mesothelin)
|
MSLN positive
|
Oncomine™ Dx Target Test
|
Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
Share via
